



Senseonics[®]

ADA
Analyst Event

June 2026

Disclaimer

This presentation has been prepared by Senseonics Holdings, Inc. (the “Company,” “Senseonics,” “we,” “us”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding expectations for future financial or other performance including projected revenue, gross margin, earnings, expenses, cash utilization, and EBITDA growth, statements regarding plans, objectives and goals for future operations, statements about the future growth of Eversense® products, statements regarding planned initiatives, investments or marketing or other programs of Senseonics, statements regarding progress and timing of collaboration and rate of adoption or growth with respect to Eversense, or its patients and providers, or the potential to enhance patient outcomes, statements regarding increasing patient access, adoption and market share, and the future growth of the CGM market, statements regarding advancing development programs and potential regulatory events, approvals and availability and the attributes of future products, including launch timing of Gemini and Freedom, features and integrations, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned” and similar expressions constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and projections about future events, and such statements are, by their nature subject to risk and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including insurer, regulatory, tender authority, and administrative processes and decisions; the development and registration and roll-out of new technology and solutions; the satisfaction of conditions for, closing of transactions related to, and assumption of European commercial responsibility for Eversense from Ascensia and the continued transition of commercial responsibility and buildout of those functions at Senseonics; coordination with health systems, health authorities, and new collaboration partners and third parties; the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics’ and its partners’ activities; the current economic and regulatory/political environment, including the effects of tariffs; and such other factors as are set forth in the “Risk Factors” detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this presentation represent Senseonics’ views as of the date hereof and the delivery of this presentation at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. This presentation also presents management’s goals and vision for Senseonics development programs, including without limitation the Gemini and Freedom development programs. These products are not approved by the FDA and the Freedom product is not subject to an IDE or other investigational approval. Plans, timing, specifications and other details of these programs are subject to change based on the factors above. The forward-looking statements in this presentation should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense®E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense CGM Systems are prescription devices; patients should talk to their healthcare provider to learn more. For important safety information, see <https://www.eversenseddiabetes.com/safety-info/>.



Senseonics[®]

Introduction

Tim Goodnow

Chief Executive Officer



Senseonics.

Redefining CGM.



Disruptive
Technology



Energized
Platform



Focused
Strategy



Commercial
Momentum



Clear
Roadmap



Agenda

Senseonics analyst event at ADA 2026


- 7:00am CT Welcome and Introduction (Tim Goodnow, CEO)
- 7:10am CT Clinical Update (Dr. Fran Kaufman, CMO)
- 7:20am CT Eversense Experience (Dr. David Ahn)
- 7:35am CT Eversense 365 Commercial Strategy (Brian Hansen, CCO)
- 7:45am CT Pipeline Update (Mukul Jain, COO)
- 7:55am CT Financial Update (Rick Sullivan, CFO)
- 8:00am CT Q&A



Redefining CGM: We Approach Diabetes Differently

A large and growing market dominated by similar products with significant draw backs

Global CGM Market Size



Common CGM Frustrations

- Early failures
- Accuracy issues
- Wasted sensors
- Skin irritation
- Compression lows
- Alarm fatigue

*Medtech Market Intelligence Report: CGM Market Mass Device (October 2025)



eversense.365
Continuous Glucose Monitoring System

The world's first and only
One Year CGM



Longest
lasting CGM



No more
repeated day 1



Gentle skin
interaction



Exceptional
accuracy



Reduced
compression lows



Industry-leading
survivability



twiist

Now available with an
A1D system (U.S.)

Product claims on this slide are derived from sources on file at Senseonics and user manuals of competitor products

Executing on Our Commercial Strategy

We have been investing for growth and it is delivering a tangible impact. The commercial strategy is working and we have recently raised over \$112m in growth capital to continue to scale.

Strategic priorities

- 1 Awareness
- 2 Access
- 3 Market Penetration
- 4 Retention

Highlights

Significant lead generation from patients (DTC) and HCPs

Growth of the inserter network and EON Care business unit

Product differentiation and the European 365 launch

Strong patient satisfaction with further enhancements to the customer experience

A Fully-Integrated and Energized Platform

Already unlocking potential and accelerating growth as and-to-end commercial organization

Key benefits of the One Company transition:



Unlocked **operational** efficiencies

Simplified workflow and communication, freeing resource to drive strategy



Accelerated our **commercial** execution

A new level of control, agility and investment to support robust growth



Enhanced **financial** profile

Increased revenue share and better margins

New look.

Same Values.


Enhanced Proposition.

A successful integration:

1. Maintained Momentum
2. Limited Disruption
3. Evolved Processes
4. Retained Best Talent
5. Enhanced Team

Investment Translating to Growth and Momentum

Our commercial strategy delivered strong results in 2025 and this has continued into 2026



Investment Highlights



Disruptive Technology

Addressing key patient pain points in a large, growing and underpenetrated CGM market

- ✓ #1 longevity – now available with AID
- ✓ Validation from real-world evidence



Energized Platform

Integration has unlocked operational efficiencies, commercial agility and financial benefits

- ✓ A new level of control and agility
- ✓ Topline accretion and margin expansion



Focused Strategy

Executing a clear growth strategy focused on awareness, access, scale and retention

- ✓ On track for ambitious growth targets
- ✓ \$112m+ growth capital raised



Commercial Momentum

Initiatives and investments are delivering consistent growth and validating our strategy

- ✓ FY 2025 revenue growth of 57% (YoY)
- ✓ Q1 revenue growth of 87% (YoY)



Clear Roadmap

Building a sustainable financial profile whilst redefining CGM, today and tomorrow

- ✓ FY guidance raised to \$60m–\$64m (in Q1)
- ✓ Pipeline catalysts: Gemini and Freedom

Our Journey is Just Getting Started

We believe in transforming lives in the diabetes community and pushing the boundaries of sensing technology to improve health and wellbeing, as we innovate with a mission to make diabetes less visible.



Yesterday

Short-term CGM

Traditional CGMs were an important step from BGM



Today

Long-term CGM

Eversense 365 is designed for people who demand more



Tomorrow

Invisible CGM

The future is no on-body transmitter



Senseonics[®]

Clinical Update

Dr. Fran Kaufman

Chief Medical Officer

Real-World Data Analysis of Large Patient Dataset – In Open-Loop

METHODS

- Anonymized sensor glucose (SG) data from Eversense Data Management System (DMS) for the first ~5000 sensors in the US
- Glucometrics comparing the first and second 6-months
- Mean SG, glucose management indicator (GMI), percent in glycemic ranges and achieving hypoglycemic targets, and 24-hour median transmitter wear time calculated
- Age, type of diabetes, and gender self-reported

RESULTS

- The first 5059 real-world 365 CGM sensors
- Mean age 55 years; 38% male, 26% female, 35% not reported or other
- 26% T1D, 56% T2D, 18% not reported
- All in open loop (MDI, including with Afrezza, or open loop pump therapy)
- DMS provided a mean of 27990 ± 16551 CGM readings per sensor

Results - Glucometrics

In open-loop

Sensor	Days sensor use	Demographics		Wear Time % (median)	Glucometrics (mean)		
		Mean age years (SD)	N of Sensors*		SG mg/dL (SD)	SG mmol/L (SD)	GMI % (SD)
Eversense 365 day	1-180	55.2 (15.0)	3580	93.72	160.40 (36.72)	8.91 (2.04)	7.15 (0.88)
	≥180- 365	54.8 (14.7)	1479	94.02	159.95 (33.04)	8.89 (1.84)	7.14 (0.79)
	All days	55.1 (14.9)	5059	93.83	160.27 (35.68)	8.90 (1.98)	7.14 (0.85)

*365-day sensors have been inserted for variable time periods as FDA approval was Q4 2024 (median sensor insertion time: 145 days)

Results - Glucometrics

In open-loop

Sensor	Days sensor use	Demographics N of Sensors*	Percent Time in Glucose Ranges (SD)						Hypoglycemic target	
			< 54 mg/dL (3 mmol/L)	< 70 mg/dL (3.9 mmol/L)	70-140 mg/dL (3.9 – 7.8 mmol/L)	70-180 mg/dL (3.9 – 10 mmol/L)	> 180 mg/dL (10 mmol/L)	> 250 mg/dL (13.9 mmol/L)	% of users time <70 mg/dL < 4%	% of users time <54 mg/dl < 1%
Eversense 365	1-180	3580	0.80 (2.46)	3.11 (5.41)	41.92 (21.68)	65.90 (21.76)	30.99 (22.40)	10.01 (13.57)	76.63	82.00
	≥180- 365	1479	0.66 (1.40)	2.85 (3.99)	41.83 (20.71)	66.34 (20.47)	30.82 (20.94)	9.41 (11.69)	76.27	80.05
	All days	5059	0.76 (2.21)	3.03 (5.04)	41.89 (21.40)	66.03 (21.39)	30.94 (21.98)	9.84 (13.05)	76.65	81.52

*365-day sensors have been inserted for variable time periods as FDA approval was Q4 2024 (median sensor insertion time: 145 days)

Results – Glucometrics by Age Range

In open-loop

Sensor	Age bins (years)	Demographics		Wear Time % (median)	Glucometrics		
		Mean age years (SD)	N of Sensors*		SG mg/dL (SD)	SG mmol/L (SD)	GMI % (SD)
Eversense 365	18-25	20.9 (1.9)	139	91.01	167.57 (42.12)	9.31 (2.34)	7.32 (1.01)
	25-45	36.0 (5.6)	1074	91.88	167.15 (38.83)	9.29 (2.16)	7.31 (0.93)
	45-60	52.7 (4.3)	1676	93.21	162.43 (37.67)	9.02 (2.09)	7.20 (0.90)
	60+	68.8 (6.3)	2141	95.38	154.73 (30.82)	8.60 (1.71)	7.01 (0.74)
	65+	71.6 (5.3)	1524	95.63	154.02 (30.09)	8.56 (1.67)	6.99 (0.72)
	All 365 sensors	55.1 (14.9)	5059	93.83	160.27 (35.68)	8.90 (1.98)	7.14 (0.85)

*365-day sensors have been inserted for variable time periods as FDA approval was Q4 2024 (median sensor insertion time: 145 days)

Results – Glucometrics by Age Range

Sensor	Age bins (years)	N of Sensors*	Percent Time in Glucose Ranges (SD)					Hypoglycemic target		
			< 54 mg/dL (3 mmol/L)	< 70 mg/dL (3.9 mmol/L)	70–140 mg/dL (3.9 – 7.8 mmol/L)	70–180 mg/dL (3.9 – 10 mmol/L)	> 180 mg/dL (10 mmol/L)	> 250 mg/dL (13.9 mmol/L)	% of users time <70 mg/dL <4%	% of users time <54 mg/dL <1%
Eversense 365	18–25	139	1.15 (1.54)	4.37 (4.54)	39.48 (21.79)	59.40 (22.67)	36.23 (23.40)	14.72 (16.64)	58.21	62.69
	25–45	1074	1.18 (2.32)	4.25 (5.43)	38.19 (21.03)	59.32 (21.65)	36.42 (22.66)	13.75 (14.88)	62.29	67.52
	45–60	1676	0.76 (2.60)	2.98 (5.37)	40.59 (22.31)	64.62 (22.24)	32.40 (23.12)	10.48 (13.70)	78.73	82.87
	60+	2141	0.51 (1.77)	2.36 (4.43)	44.87 (20.40)	70.90 (19.22)	26.73 (19.71)	7.06 (10.39)	83.75	89.06
	65+	1524	0.48 (1.87)	2.29 (4.52)	45.23 (20.06)	71.53 (18.61)	26.18 (19.08)	6.70 (10.07)	85.18	90.19
	All sensors	5059	0.76 (2.21)	3.03 (5.04)	41.89 (21.40)	66.03 (21.39)	30.94 (21.98)	9.84 (13.05)	76.65	81.52

*365-day sensors have been inserted for variable time periods as FDA approval was Q4 2024 (median sensor insertion time: 145 days)



Technology That Can Improve Your Life with T1D

David Ahn, MD

Chief of Diabetes Services at Hoag

Dr. Kris V. Iyer Endowed Chair in Diabetes Care

hoag[®]

Mary & Dick Allen
Diabetes Center

David Ahn, M.D.



**Mary & Dick Allen Diabetes Center at
Hoag Hospital
Newport Beach, California**

My Experience with Eversense 365 and the Insertion Procedure

- I have had hundreds of sensors in my patients
 - Appreciate all of its unique features to offer something truly innovative for my patients
- I have done over 350 procedures
 - For my practice as well as for referrals
- I easily fit the procedures into my practice
- I have had essentially zero adverse events related to the procedures
- My patients are truly satisfied with Eversense 365

What Does twiist + Eversense Offer that are Differentiators



- Almost all settings matter for algorithm
- Widest target range 87-180
- Can override suggested bolus
- Have active carb assessment
- Add meal quality – lollipop, taco, pizza
- Premeal setting to bring glucose down before eating
- Exquisite insulin delivery and occlusion detection
- 19 minutes vs 180 Omnipod, 150 780G, 171 iLet, 40-64 Tandem
- Pump lightweight, can wear on body
- Cartridge holds 300 units
- Deliver insulin from a button on the pump



- ADVANTAGES of Eversense 365 CGM in an AID
- One Sensor - One Year
- No Interruptions/Disruptions
- No repeated day 1 data – higher MARD
- Moving only 1 device, not 2
- No More 3D Chess Game For Sensor/Pump Placement
- Accuracy, low range, no compression lows
- Gentle on Skin
- Removeable Transmitter, MRI, etc.

Preliminary Data from Integration with twiist AID – Real-World Presented at ATTD, Barcelona, March, 2026

- Full commercial launch February 19, 2026, with data analysis March 2, 2026
- 122 sensors > 7days since integration with twiist
- Mean age 45 years; 64% T1D
- Median transmitter wear time – 99%
- Mean SG – 144.3 mg/dL (8.05 mmol/L)
- GMI % - 6.76


< 54 mg/dL (3 mmol/L)	< 70 mg/dL (3.9 mmol/L)	70-140 mg/dL (3.9 – 7.8 mmol/L)	70-180 mg/dL (3.9 – 10 mmol/L)	> 180 mg/dL (10 mmol/L)	> 250 mg/dL (13.9 mmol/L)
0.51 (1.09)	2.76 (3.54)	53.94 (20.53)	76.62 (17.04)	20.61 (17.76)	5.15 (10.86)



Case Report - 1


- 31 year old female diagnosed at 12 years of age with T1D
- On open loop pump therapy from diagnosis – unable to use all traditional transcutaneous sensors due to skin sensitivity and accuracy issues
- A1C was increasing, as was hypoglycemia, until she started Eversense 01/2019 which she tolerated without skin or accuracy issues
- Did well but wanted to use an AID as soon as one was integrated with Eversense
- Limited launch with twiist starting 12/2025

Open loop pump without CGM- Lows almost every day and Highs



Eversense with Open Loop Pump – Hypoglycemia Improved


Sunday Nov 26, 2023







Statistics	
Very High > 250 mg/dL	2.19%
High 181 - 250 mg/dL	25.55%
In Range 70 - 180 mg/dL	67.88%
Low 54 - 69 mg/dL	3.65%
Very Low < 54 mg/dL	0.73%
Average Glucose	160 mg/dL
Standard Deviation	44.4 mg/dL
Number of High Alerts	7
Number of Low Alerts	3

12 AM - 4 AM	4 AM - 8 AM	8 AM - 12 PM	12 PM - 4 PM	4 PM - 8 PM	8 PM - 12 AM
12:20 AM High Alert - 186 mg/dL	07:15 AM High Alert - 187 mg/dL	09:15 AM High Alert - 216 mg/dL	02:05 PM Low Alert - 61 mg/dL	06:10 PM High Alert - 185 mg/dL	10:05 PM Low Alert - 64 mg/dL
12:38 AM Calibration - 159 mg/dL		11:15 AM High Alert - 187 mg/dL	02:35 PM Low Alert - 71 mg/dL		11:00 PM High Alert - 207 mg/dL
		11:45 AM High Alert - 192 mg/dL			

On Eversense 365 with twiist Integration Started 12/09/25



Twist Integration with Eversense 365 – an Average Day



Total Carbs [ⓘ] 171g


Std. Deviation (CGM) (104 - 189) [ⓘ] mg/dL
42

CV (CGM) [ⓘ] 29%

Case Report – 2

29M Police Officer / SWAT

- Eversense + MDI since 2020
- Started Twiist 1/2/2026
- Failed other CGM's due to adhesive issues
- Prefers vibratory alerts
- A1c 7.5 (11/2025)



14 Days: Dec 19 2025 - Jan 01 2026

Eversense Wear Time: 95.8 %

Glucose Metrics

Average Glucose 143 mg/dL

Goal: <154 mg/dL

Glucose Management Indicator (GMI) 6.7%


Goal: <7 %

Glucose Variability 44.4%

Defined as percent coefficient of variation

Goal: ≤ 36 %

Case Report – 2



14 Days: Jan 02 2026 - Jan 15 2026

Eversense Wear Time: 100 %

Glucose Metrics

Average Glucose 132 mg/dL

Goal: <154 mg/dL



Glucose Management Indicator (GMI) 6.4%

Goal: <7 %

Glucose Variability 39.4%


Defined as percent coefficient of variation

Goal: ≤ 36 %




Ambulatory Glucose Profile

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if they occurred in a single day.




Daily Glucose Profile

Each daily profile represents a midnight-to-midnight period.




Ambulatory Glucose Profile

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if they occurred in a single day.



Daily Glucose Profile

Each daily profile represents a midnight-to-midnight period.



Case Report – 3

Omnipod + Dexcom

- 41 year old male
- Used Eversense in past
- Omnipod + Dexcom
- Started Twiist + Libre 3/20/2026

Glucose - Time In Range




Summary


GMI	SD	32 mg/dL
N/A	CV	22.6%
Average	Median	140 mg/dL
141 mg/dL	Highest	252 mg/dL
% Time CGM Active	Lowest	LO mg/dL
60.7% (8.5 days)		

Ambulatory Glucose Profile (AGP)

Target Range (70 - 180 mg/dL) 25 - 75% Lowest - Highest
Median 10 - 90%



twiist + FSL3+



twiist + E365





Conclusions

- My patients improved first with Eversense 365 in open-loop and then further improvement with Eversense and twist integration
- My patients appreciate Eversense 365 and come back for the next sensor
 - Very high rates of patient satisfaction
- Why I discuss Eversense 365 with my patients:
 - Duration, accuracy, sensor doesn't fall off, skin problems, discretion with vibratory alerts, no dislodgement, no compression lows, advantages with exercise, concern about hypoglycemia/hypoglycemia unawareness
 - I believe in choice
 - I like to do the procedure
 - The future pathway is truly exciting

Thank You!



David.Ahn@hoag.org



@AhnCall



@DiabetesDoc





Senseonics®

Commercial Strategy

Brian Hansen
Chief Commercial Officer

Growth Initiatives and Investments

We are focused on driving growth and unlocking the potential of Eversense 365.

1

Awareness

DTC marketing

HCP marketing

Optimize targeting and product positioning

2

Access

Expand and optimize inserter network (inc. EON Care strategy)

Further expand coverage

Enhance Patient affordability

3

Penetration

Expand commercial team and capacity

Refocus approach to the European market

AID* market expansion

4

Retention

Refine onboarding process

Enhance user experience

Provide proactive support, with focus on renewals

Supported by improved operational control and financial firepower – \$112m+ growth capital raised

Encouraged by recent commercial momentum and focused strategy

Channel CONVERSION FUNNEL

Focus on generating high-quality leads, increasing reachability, driving efficient conversion

DTC Channel

(~60% of Shipments)

Core Role:

- Broaden awareness of Eversense

Structural Reality


- High inbound demand exists
- Channel driven by DTC investment
- Growth moderated by mid-funnel conversion

Primary Levers

- Accelerate speed-to-lead and reachability
- Increase workable-to-opportunity conversion
- Advance AI-enabled nurturing and outbound
- Improve scheduling and reimbursement friction

Implication

- Small improvements in mid-funnel conversion drive shipment lift.



Health Care Professional (HCP) Channel

(~40% of Shipments)

Core Role:

- Strategic expansion & long-term positioning

Structural Reality

- Underpenetrated prescriber base
- Referral driven, more durable demand
- Dependent on office activation & support

Primary Levers

- Expand targeted HCP coverage
- Increase office activation & referrals
- Enhance field & clinical support
- Grow EON inserter network

Implication





- HCP growth expands professional awareness and growth.

U.S. Territory Manager Coverage



SALES FORCE

64
TEAM MEMBERS

 Territory Managers	45
 Associate Territory Managers	8
 Regional Clinical Managers	5
 Area Managers	6

EON *Care*: Expanding Access

A purpose-built subsidiary increasing insertion convenience to improve patient access nationwide

Extends reach
to untapped
patients

Enables
prescriber-only
physicians*

Boosts
field-sales
efficiency

Centralized
scheduling &
patient training

Reimbursable
and self-
funding

Our priorities:

1. Activate More Inserters



We expect to more than
double the number of Eon
providers in 2026

Future Growth Accelerators

- EON target expansion of **50+ new providers** over next 12 months
- **Recruitment partner contracted**
– acceleration well underway

2. Commercial Optimization




Leaning into EON
for growth

SCALE: EON is <10% of all
inserters but now **handles**
~33% of insertions

Addressing Patient Unmet Needs

Insights from patients and practitioners showcase product differentiation and real-life benefits.

90% of new patients now coming from competitors



I'll never go back to other CGMs
Best move I've made
Total game changer
Best CGM I've ever used
Accuracy is great
Most reliable
Removable for convenience
So easy to manage
No more adhesive allergies
Really decreases the burden

Fits into my lifestyle
I recommended it to my HCP, now she's a prescriber
Keeps getting better
Going on year 2

Our First AID Integration

Encouraging early uptake and patient impact of our first AID combination, following the strategic partnership with Sequel



- ✓ Transformative combination of two disruptive technologies
- ✓ Access to U.S. patients that prefer to use an insulin pump
- ✓ Enables real-time readings from Eversense® to be received by the twiist™ pump
- ✓ Readings used in the Loop algorithm automatically adjust insulin delivery
- ✓ Eversense 365 provides the longevity, continuity and accuracy essential for AID systems
- ✓ Encouraging real-world evidence of performance, glucometrics and clinical impact*

Technology you can trust
—WORKING TOGETHER.



European Market Transfer & launch

Significant progress in bringing Eversense 365 to new geographies after CE Mark in January 2026



SWEDEN

LAUNCHED
April 2026

Tender market

Commercial launch



SPAIN

LAUNCHED
May 2026

Tender market

Commercial launch



GERMANY

EXPECTED LAUNCH
June 2026

Non-tender market

Transfer in progress



ITALY

EXPECTED LAUNCH
June 2026

Tender market

Transfer in progress

~60 employees across four European markets



Senseonics[®]

Pipeline Update

Mukul Jain

Chief Operating Officer

Product Vision

Our technology is redefining diabetes care today and tomorrow. We are pushing the boundaries of CGM with long-term implantable products that are designed to empower better diabetes management and reduce the device burden.



One sensor.

All patient segments.

- ✓ No sensor changes for a year
- ✓ No transmitter
- ✓ No daily calibration

Gemini

The first CGM with an optional on-body transmitter, enabling two unique products from one platform

Designed for FLEXIBILITY.



Enhanced Eversense 365 sensor with integrated 1-year battery and updated algorithm



Full year use with one sensor and one calibration per week
Real-time CGM with transmitter or standalone FGM* without transmitter



For insulin and food decision making, as well as for AID



Freedom

Elimination of transmitter by incorporating Bluetooth into the sensor



Designed for FREEDOM.



Enhanced Eversense 365 sensor with integrated 1-year battery and Bluetooth, as well as updated algorithm



Full year use with one sensor and one calibration per week
No transmitter included in the system
Direct communication between sensor and handheld



For intensively managed patients who want better control

Pipeline Timeline

Gemini and Freedom are built on the same sensor technology as Eversense 365

	2026	2027	2028
Eversense 365 World's first one-year CGM sensor	OUS launch		
Gemini Same one-year sensor with battery added, for continuous and optional point-in-time reading	Clinical study	Launch	
Freedom Same one-year sensor and battery, with Bluetooth to enable direct handheld communication		IDE Clinical study	Launch

The Gemini Study

Gemini pivotal clinical study in progress with commercial launch in Q2 2027

- *Designed to demonstrate the scan feature for intermittent use*
- *Subjects inserted with Eversense 365 in one arm and Gemini in the other arm*
- *Study duration is 3-months post insertion and will complete Q4 2026*
- *510(k) submission expected Q1 2027*

The Freedom System in More Detail

Key but de-risked technology advancements beyond the Gemini system

Sensor

- Sensing ASIC – No change from Gemini
- Communication – Off the shelf BLE chip and antenna
- Build – Sensor build in progress for first-in-human

Battery

- Proven technology manufactured by Integer
- Gen 2 battery chemistry but same form factor
- Capacity confirmed to meet the targets (~1 month buffer)
- Build complete to support first-in-human
- Production read in Q1 2027



The Foundations for Freedom








Animal study in Q2 2026 laid the foundation for first-in-human sensor design

Study details:

- 3 Animals, 2 sensor design (antenna) variants, 2 implant locations
- Performance is the cumulative connection rate through 50 days for distance up to 25 ft
- Johanson antenna is preferred (off-the-shelf component) and shows less variability
- Insertion location seems to be a factor


Preferred sensors demonstrated:

- 1) Communication 100% of the time within 8ft distance
- 2) Approx. 83% connection success across 3 different enclosures (up to 25 ft) over 7 weeks (~18,500 data points)

SENSOR & STUDY DESIGN				PERFORMANCE	
Sensor	Antenna	Insertion Location	Animal ID	Avg RSSI (dBm)	Connection Success
8FB909	Helical	R – Lateral Hip	S17-133-001	-56	
B2E356	Johanson	R – Lateral Hip	S17-133-002	-51	
9BF782	Johanson	R – Behind Ear	S17-133-001	-57	
F4C556	Helical	L – Behind Ear	S17-133-003	-56	
830121	Helical	R – Behind Ear	S17-133-003	-61	
EEE7EF	Helical	L – Lateral Hip	S17-133-002	-57	
6225CB	Helical	L – Lateral Hip	S17-133-001	-72	

The Path to Freedom

- Q3 2026 – First-in-human clinical study
- Q1 2027 – IDE submission
- Q2 2027 – 3-month pivotal study to demonstrate BLE communication
- Q1 2028 – 510(k) submission



A man with short dark hair and a beard, wearing a light blue t-shirt and light-colored pants, is sitting on a metal mesh chair outdoors. He is looking down and to the left. To his left, a large, fluffy brown and white dog is sitting on the ground, looking towards the man. The background shows a house with large windows and lush green trees. The entire scene is overlaid with a semi-transparent blue filter.

Senseonics[®]

Financial Update

Rick Sullivan

Chief Financial Officer

Strengthening the Balance Sheet

Two transactions adding \$100M+ in growth capital — funding operations through the anticipated launch of Freedom in 2028

Equity Offering – May 2026

- 10.2M common shares + 8.0M pre-funded warrants (18.2M total)
- Strong Institutional support; 80%+ from 5 institutional investors
- Net proceeds ~\$86.5M after underwriting fees
- ATM program (~\$94M capacity)

Hercules Capital Credit Facility Amendment – May 2026

- Additional \$20M funded at close
- Interest rate: Prime ~9.9% | Maturity: September 1, 2027
- Additional \$85M available across future tranches (revenue milestones)

COMBINED IMPACT

Cash & Investments **\$64.6M** → **~\$164.6M**

PRO-FORMA CAPITALIZATION (as of Q2 2026)

	Pre-Financing	Post-Financing
LIQUIDITY		
Cash & Investments	\$64.6M	~\$164.6M
Debt Outstanding (HCI)	\$35.2M	\$55.0M
Total Facility Available	\$100.0M	\$140.0M
Net Cash	~\$29.4M	~\$109.6M
SHARE STRUCTURE		
Basic Shares Outstanding	41.8M	52.0M
PHC Pre-funded Warrants	4.2M	4.2M
New Pre-funded Warrants	—	8.0M
Warrants (WA Strike \$7.40)	2.4M	2.4M
Options (WA Strike \$21.77)	1.7M	1.7M
RSUs	1.0M	1.0M
Fully Diluted Shares	51.1M	69.3M

Eversense U.S. Revenue Streams

Sales channels

DTC CHANNEL

Social Media & Digital Advertising

Patient leads via targeted social campaigns and digital platforms → scheduling workflow

HCP CHANNEL

Field Sales Representatives

Physician leads via sales reps → office implantations and CDM engagement

REORDERS

Patient Renewals

Existing patients retained on Eversense feed back into both reimbursement channels

Reimbursement channels

DME CHANNEL

Distributors with Insurance Payor Contracts

40%
of volume

BUNDLED PAY (BP)

Product + Procedure Fee

★ Notably higher ASP

60%
of volume

Bundled Pay ASP meaningfully exceeds DME channel ASP

Revenue streams

DISTRIBUTOR

Direct to Distributor (DME)

Product Revenue Only

Insurance contracts held by distributor

EON CARE — Procedure

Commercial Payors

Procedure Revenue

Contracted through EON Care; commercial insurance payor network

EON CARE — Bundled Pay

Medicare and Commercial Payors

Product + Procedure Revenue

Medicare and Commercial reimbursement via EON Care platform

CONSIGNMENT

Bundled Pay Physicians

Product Revenue Only

Inventory held at physician; revenue recognized on use

Building a Sustainable Financial Profile

Well-positioned to reach our target of long-term profitability.

Realizing near-term revenue

Where We Are Today (Q1 2026)

- **\$11.7M revenue**
- +85% year-over-year growth
- **58% gross margin**
- (54% ex. one-time benefit)
- \$32.3M net loss (\$0.71/share)
- **\$64.6M cash as of 3/31/26**
- \$35.2M debt outstanding
- Full commercial control regained
- **\$100M+ growth capital raised in Q2 2026**

Expanding topline growth

2026: Updated guidance following strong Q1 results

- **Revenue: \$60M–\$64M**
- Raised from \$58M–\$62M; +70%–82% YoY
- **Gross Margin: 55%–58%**
- Increasing in back half of year
- Seasonality: ~40% H1 / ~60% H2
- Operating Expenses: \$150M–\$160M
- Cash Utilization: \$110M–\$120M
- EU launches: Sweden ✓ Spain ✓
- Germany & Italy expected June 2026

Achieving scale

Goal: Future state as a fully-integrated business

- Sustainable earnings growth
- **70%+ gross profit margin**
- EBITDA breakeven and profitability
- Self-funded R&D and development pipeline
- **Freedom platform launch (2028)**
- AID integration with multiple partners

The Journey Ahead

We have growth levers to pull and catalysts ahead. We are now in control of our destiny.

Senseonics™

US commercial integration
Completed January 1st

eVersense.365
Continuous Glucose Monitoring System


CE Mark Approval
Received January 29th

2026

eVersense.365
Continuous Glucose Monitoring System

+
twiist™

First AID integration
Launched February 19th



Planned Connectivity Updates



BGM Connectivity Direct communication with Bluetooth enabled blood glucose meters
Further Pump Integration Sensor augments pump, planning additional pump partnerships
Pump AID CGM controls pump



Q&A.

Redefining CGM.



Disruptive
Technology



Energized
Platform.



Focused
Strategy



Commercial
Momentum



Clear
Roadmap

